In conclusion, the results of the present study suggest that the cholangiocarcinoma (CHOL)-hub genes (SNX15, ATP2A1, PDCD10, BET1, and HMGA2) can be used as biomarkers of tumor progression, metastasis, therapy outcome, and poor prognoses of CHOL. Here, HMGA2 is linked to neoplasm.